Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-escalation study of CBL-514 injections for thigh subcutaneous fat reduction
ACTRN12620001153909Phase 2Not yet recruiting
- Sponsor
- Caliway Biopharmaceuticals
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of CBL-514 in localized adiposity (AL) (4 arms), sponsored by Caliway Biopharmaceuticals. Primary endpoint: Safety and tolerability following single dose of CBL-514. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
CBL-514
03
Conditions
localized adiposity (AL)
Beyond the preview
Go deeper on ACTRN12620001153909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001153909.